Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder
Mathieu Rouanne, Dean F. Bajorin, Raquibul Hannan, Matthew D. Galsky, Stephen B. Williams, Andrea Necchi, Padmanee Sharma, Thomas Powles
Topics & Concepts
AtezolizumabMedicinePembrolizumabNivolumabDurvalumabIpilimumabAvelumabCystectomyOncologyImmune checkpointBladder cancerNeoadjuvant therapyTremelimumabImmunotherapyInternal medicineBlockadeCancerBreast cancerReceptorBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers